{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:52:48Z","timestamp":1791057168130,"version":"4.1.0"},"reference-count":77,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,10,23]],"date-time":"2008-10-23T00:00:00Z","timestamp":1224720000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p>As a result of intensive investigation, particularly in the pharmaceutical industry, a number of potent and selective metabotropic glutamate receptor subtype 5 (mGluR5) antagonists have been discovered. The structure activity relationship studies that led to the discovery of these mGluR5 antagonists are presented in this review. Results from studies on selected mGluR5 antagonists in animal models that simulate drug reward, reinforcement, and relapse appear promising. The comorbidity between drug abuse and anxiety and depression make drugs active in these disorders of great interest. Clinical studies showed that the mGluR5 antagonist fenobam was an active anxiolytic drug. Several new mGluR5 antagonists produced anxiolytic and antidepressant\u2010like effects in animal models of these disorders. The results from the clinical and animal studies provide information for new approaches to finding mechanistically distinct pharmacotherapies to help patients achieve and maintain abstinence from cocaine, methamphetamine, opiates, ethanol, and nicotine (smoking).<\/jats:p>","DOI":"10.1196\/annals.1441.015","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T12:00:36Z","timestamp":1249992036000},"page":"221-232","source":"Crossref","is-referenced-by-count":49,"title":["Antagonists at Metabotropic Glutamate Receptor Subtype 5"],"prefix":"10.1196","volume":"1141","author":[{"given":"F. Ivy","family":"Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,23]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026054750290"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573400054065578"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2006.00149.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(97)00090-7"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.17.4.371"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.12.12.1845"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.14.11.1593"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.37.1.205"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(94)00129-G"},{"key":"e_1_2_8_11_2","doi-asserted-by":"crossref","first-page":"13361","DOI":"10.1016\/S0021-9258(18)42219-3","article-title":"Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate\/Ca2 +signal transduction","volume":"267","author":"Abe T.","year":"1992","journal-title":"J. Biol. Chem."},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(95)00085-K"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1349"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.45.28612"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0720157.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)01141-4"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(01)00767-3"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00272-8"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.040618"},{"key":"e_1_2_8_20_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0022-3565(24)34881-5","article-title":"SIB\u20101757 and SIB\u20101893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5","volume":"290","author":"Varney M.A.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00082-9"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006230200"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1358\/dnp.2004.17.4.829052"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01694-1"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm025570j"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.05.037"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.09.042"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm050570f"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.06.099"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.06.078"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm070078r"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm049828c"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.09.016"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.09.012"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.09.011"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.09.018"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2003.10.021"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.03.066"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.06.030"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.11.078"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.06.059"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.12.083"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.04.032"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.12.088"},{"key":"e_1_2_8_45_2","first-page":"708","article-title":"The clinical and quantitative EEG effects and plasma levels of fenobam (McN\u20103377) in subjects with anxiety: An open rising dose tolerance and efficacy study","volume":"24","author":"Itil T.M.","year":"1978","journal-title":"Curr. Ther. Res."},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600840212"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.089839"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.12.033"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.11.092"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5335.52"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.13.1689"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0173(93)90013-P"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.psych.54.101601.145237"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1583"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2004.11.001"},{"key":"e_1_2_8_56_2","doi-asserted-by":"crossref","unstructured":"Glantz M.D.&C.R.Hartel Eds.1999.Drug Abuse: Origins and Interventions.American Psychological Association. Washington DC .","DOI":"10.1037\/10341-000"},{"key":"e_1_2_8_57_2","volume-title":"Glutamate and Addiction","author":"Herman B.H.","year":"2003"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2000.tb00199.x"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2003.11.002"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1300.009"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001269"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012419239-3\/50039-4"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn0901-873"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2069-2"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.03.053"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1432-z"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10166"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(02)00309-X"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300381"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0217-y"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.078733"},{"key":"e_1_2_8_72_2","first-page":"863","article-title":"Selective mGlu5 receptor antagonist MTEP attenuates naloxone\u2010induced morphine with\u2010drawal symptoms","volume":"56","author":"Palucha A.","year":"2004","journal-title":"Pol. J. Pharmacol."},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.10.007"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.05030503"},{"key":"e_1_2_8_75_2","first-page":"315","volume-title":"Techniques in the Behavioral and Neural Sceinces (Handbook of Stress and the Brain, Part 2)","author":"Lu L.","year":"2005"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0211"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.04.007"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152707780363302"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1441.015","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1441.015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T18:26:06Z","timestamp":1739298366000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1441.015"}},"subtitle":["Structure Activity Relationships and Therapeutic Potential for Addiction"],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1196\/annals.1441.015"],"URL":"https:\/\/doi.org\/10.1196\/annals.1441.015","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}